Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRF5 inhibitor (Totus Medicines)
- Development stage
- Preclinical
- Lead developer
- Totus Medicines
- Modality
- Covalent Small Molecules → Small Molecules
01
Overview
Totus Medicines is developing an unnamed covalent small-molecule inhibitor targeting Interferon Regulatory Factor 5 (IRF5) for the treatment of various autoimmune and inflammatory diseases. IRF5 is a transcription factor that acts as a master regulator of the type I interferon pathway and pro-inflammatory cytokine production. By utilizing its proprietary OmniDEL platform, Totus has designed a covalent inhibitor to irreversibly block IRF5 signaling, which is genetically validated but has historically been considered undruggable. The program is currently in the IND-enabling preclinical stage for indications including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, and dermatomyositis.
- Other names
- IRF5 inhibitorIRF-5 inhibitorIRF 5 inhibitorTotus IRF5 program
02
Targets
IRF5 (Interferon regulatory factor 5)
Beyond the preview
Go deeper on IRF5 inhibitor (Totus Medicines).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRF5 inhibitor (Totus Medicines).